- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer | Clinical
EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions
June 29, 2022
Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.
Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer
June 27, 2022
During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.
Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC
June 27, 2022
In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.
Tazemetostat Results Signal the Utility of Biomarker-Driven Therapy for BAP1-Inactivated MPM
June 24, 2022
Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
June 22, 2022
During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.
Ramucirumab/Pembrolizumab Combo as Potential Treatment for NSCLC
June 16, 2022
Karen L. Reckamp, MD, discusses the Lung-MAP nonmatched substudy S1800A for patients with non–small cell lung cancer who were previously treated with immune checkpoint inhibitors and develop resistance.
Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC
June 13, 2022
During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.
FDA Accepts sBLA for Pembrolizumab in Stage IB, II, or III NSCLC
June 13, 2022
A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.
KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC
June 09, 2022
In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.
Sugemalimab Plus Chemotherapy Demonstrates Durable Efficacy as First-Line Treatment in Metastatic NSCLC
June 07, 2022
At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.